Item 7.01 Regulation FD Disclosure.
Aquestive Therapeutics, Inc. (the “Company”) is furnishing this Current Report
on Form 8-K in connection with the disclosure of information, in the form of an
investor presentation, to be given at meetings with institutional investors,
analysts and others. This information may be amended or updated at any time and
from time to time through another Current Report on Form 8-K, a later company
filing or other means. A copy of the Company’s investor presentation is attached
hereto as Exhibits 99.1 to this Current Report on Form 8-K and incorporated into
this Item 7.01 by reference and replaces in its entirety all prior investor
presentations filed by the Company other than 4Q Supplemental Materials filed by
the Company on March 7, 2023, which along with this investor presentation are
available on the Company’s website located at http://www.aquestive.com, although the
Company reserves the right to discontinue that availability at any time.
The information in this Item 7.01 (including Exhibits 99.1) shall not be deemed
to be “filed” for purposes of, or otherwise subject to the liabilities of,
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), nor shall it be deemed to be incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in any such filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits. Exhibit Description Number 99.1 Aquestive Therapeutics Corporate Presentation dated March 2023
© Edgar Online, source Glimpses
postbrexitcompliance.com 